Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/04/26
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in UrticariaZacks Investment Research • 03/02/26
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatmentGlobeNewsWire • 02/27/26
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite TreatmentGlobeNewsWire • 02/27/26
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)GlobeNewsWire • 02/24/26
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisGlobeNewsWire • 02/24/26
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)GlobeNewsWire • 02/19/26
Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & SellsSeeking Alpha • 02/13/26
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating AllergyGlobeNewsWire • 02/10/26
These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 ResultsBenzinga • 02/02/26
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal DiseasesGlobeNewsWire • 02/02/26
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 01/30/26